UPCOMING EVENTS
NEWS
KaloCyte in the News: Old Line Capital Invests in KaloCyte
Old Line Capital Partners has made a significant investment in KaloCyte, Inc., to extend the research and development of break-through human blood substitute ErythroMer.
KaloCyte in the News: KaloCyte raises $300K from Maryland Momentum Fund
Months after moving to Baltimore, the company is growing its team and gaining funding from local institutions.
Press Release: KaloCyte, Inc., selected for Springboard’s Health Innovation Hub, Joins Network of more than 800 Seasoned Entrepreneurs
Elaine Haynes, president and CEO of KaloCyte, will join more than 800 experienced “been there, run that” entrepreneurs who make up the Springboard Expert Network.
Press Release: NIH Awards KaloCyte $373K SBIR Grant to Advance Synthetic Blood Product
The NIH SBIR grant will help KaloCyte develop ErythroMer™ to preclinical safety and efficacy testing.
ErythroMer in the News: Making and storing blood to save lives
KaloCyte co-founders Allan Doctor and Dipanjan Pan are featured in an article titled, “Making and storing blood to save lives”
Press Release: KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters
KaloCyte welcomes Product Development Scientist, Nivesh Mittal, PhD to propel production of ErythroMer™
Maryland Booms in the BioCapital Hotbed
Elaine E. Haynes, President and CEO of KaloCyte, Inc., featured in BioSpace article touting Maryland, a BioCapital hotbed.
Elaine Haynes Discusses Business in Maryland with the Maryland Tech Council
In this episode, Marty discusses business in Maryland with Elaine E. Haynes, President and CEO of KaloCyte, Inc., a pre-clinical biotech startup developing a synthetic red blood cell substitute.
Press Release: KaloCyte CEO to Present at NIH Innovation Conference and Life Sciences Summit
KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, has been selected to present this week at both the National Institutes of Health (NIH) Innovation Conference (NIC) and the Life Sciences Summit (LSS) in New York City.
Bold New Vision on Blood Research
New Center for Blood Oxygen Transport & Hemostasis will develop diagnostics and therapeutics that could revolutionize emergency and critical care medicine.
CONTACT US
KaloCyte, Inc.
4 N. Martin Luther King Jr. Blvd
Suite 300
Baltimore, MD 21201
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.